EUR 1.73
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 8.21 Million EUR | -27.55% |
2022 | 11.33 Million EUR | -19.92% |
2021 | 14.15 Million EUR | -7.52% |
2020 | 15.31 Million EUR | 303.19% |
2019 | 3.79 Million EUR | 339.91% |
2018 | -1.58 Million EUR | -188.1% |
2017 | 1.79 Million EUR | -46.16% |
2016 | 3.33 Million EUR | -4.93% |
2015 | 3.51 Million EUR | 71.36% |
2014 | 2.04 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.69 Million EUR | 0.0% |
2024 Q1 | 2.69 Million EUR | 37.24% |
2023 Q1 | 2.07 Million EUR | -66.04% |
2023 Q2 | 3.98 Million EUR | 92.29% |
2023 Q3 | 1.94 Million EUR | -51.34% |
2023 FY | 8.21 Million EUR | -27.55% |
2023 Q4 | 1.96 Million EUR | 1.03% |
2022 Q3 | 3.53 Million EUR | -34.88% |
2022 Q1 | 2.71 Million EUR | -56.74% |
2022 FY | 11.33 Million EUR | -19.92% |
2022 Q4 | 6.1 Million EUR | 72.88% |
2022 Q2 | 5.42 Million EUR | 99.74% |
2021 FY | 14.15 Million EUR | -7.52% |
2021 Q4 | 6.27 Million EUR | 93.65% |
2021 Q3 | 3.24 Million EUR | -61.96% |
2021 Q2 | 8.52 Million EUR | 96.79% |
2021 Q1 | 4.33 Million EUR | -35.76% |
2020 Q4 | 6.74 Million EUR | -20.16% |
2020 Q1 | 4.43 Million EUR | -44.12% |
2020 Q3 | 8.44 Million EUR | 2.75% |
2020 Q2 | 8.21 Million EUR | 85.28% |
2020 FY | 15.31 Million EUR | 303.19% |
2019 Q3 | 4.25 Million EUR | -40.25% |
2019 Q1 | 3.77 Million EUR | 23.15% |
2019 FY | 3.79 Million EUR | 339.91% |
2019 Q4 | 7.93 Million EUR | 86.73% |
2019 Q2 | 7.11 Million EUR | 88.43% |
2018 Q4 | 3.06 Million EUR | 0.0% |
2018 Q3 | 3.06 Million EUR | 38.46% |
2018 Q1 | 2.21 Million EUR | -8.53% |
2018 Q2 | 2.21 Million EUR | 0.0% |
2018 FY | -1.58 Million EUR | -188.1% |
2017 Q4 | 2.42 Million EUR | 0.0% |
2017 Q2 | 1.66 Million EUR | 0.0% |
2017 Q1 | 1.66 Million EUR | 37.51% |
2017 FY | 1.79 Million EUR | -46.16% |
2017 Q3 | 2.42 Million EUR | 45.14% |
2016 FY | 3.33 Million EUR | -4.93% |
2016 Q1 | 1.26 Million EUR | 0.0% |
2016 Q2 | 1.26 Million EUR | 0.0% |
2016 Q3 | 1.21 Million EUR | -3.88% |
2016 Q4 | 1.21 Million EUR | 0.0% |
2015 FY | 3.51 Million EUR | 71.36% |
2014 FY | 2.04 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -96.672% |
ABIVAX Société Anonyme | 127.37 Million EUR | 93.551% |
Adocia SA | 15.62 Million EUR | 47.437% |
Aelis Farma SA | 18.81 Million EUR | 56.347% |
Biophytis S.A. | 14.33 Million EUR | 42.685% |
genOway Société anonyme | 16.73 Million EUR | 50.921% |
IntegraGen SA | 5.35 Million EUR | -53.479% |
Medesis Pharma S.A. | 1.56 Million EUR | -425.064% |
Neovacs S.A. | 10.34 Million EUR | 20.578% |
NFL Biosciences SA | 4.37 Million EUR | -87.799% |
Plant Advanced Technologies SA | 2.76 Million EUR | -197.123% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -378.182% |
Sensorion SA | 27.05 Million EUR | 69.634% |
Theranexus Société Anonyme | 3 Million EUR | -173.379% |
TME Pharma N.V. | 5.49 Million EUR | -49.445% |
Valbiotis SA | 9.86 Million EUR | 16.76% |
TheraVet SA | 1.64 Million EUR | -399.601% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 59.572% |
DBV Technologies S.A. | 89.4 Million EUR | 90.812% |
Genfit S.A. | 54.8 Million EUR | 85.01% |
GeNeuro SA | 14.35 Million EUR | 42.782% |
Innate Pharma S.A. | 64.57 Million EUR | 87.277% |
Inventiva S.A. | 120.18 Million EUR | 93.165% |
MaaT Pharma SA | 21.59 Million EUR | 61.964% |
MedinCell S.A. | 32.92 Million EUR | 75.047% |
Nanobiotix S.A. | 58.92 Million EUR | 86.059% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 65.174% |
Poxel S.A. | 28.76 Million EUR | 71.441% |
GenSight Biologics S.A. | 32.66 Million EUR | 74.847% |
Transgene SA | 31.23 Million EUR | 73.696% |
Valneva SE | 134.92 Million EUR | 93.911% |